AbbVie Inc. Revenue
AbbVie Inc. (ABBV) reported Revenue of $16.99 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-03
- AbbVie Inc. revenues for the quarter ending 2026-06-30 was $16.99B, a 10.16% increase year-over-year.
- AbbVie Inc. revenues for the quarter ending 2026-03-31 was $15.00B, a 12.43% increase year-over-year.
- AbbVie Inc. revenues for the quarter ending 2025-12-31 was $16.62B, a 10.04% increase year-over-year.
- AbbVie Inc. revenues for the quarter ending 2025-09-30 was $15.78B, a 9.10% increase year-over-year.
- AbbVie Inc. revenues for fiscal 2025 was $61.16B, a 8.57% increase from fiscal 2024.
- AbbVie Inc. revenues for fiscal 2024 was $56.33B, a 3.71% increase from fiscal 2023.
- AbbVie Inc. revenues for fiscal 2023 was $54.32B, a 6.44% decline from fiscal 2022.
- AbbVie Inc. revenues for fiscal 2022 was $58.05B, a 3.30% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.99B 10-Q · filed 2026-08-03 | $31.99B 10-Q · filed 2026-08-03 | $48.61B derived: sum of 3 quarters · filed 2026-08-03 | $64.39B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $15.00B 10-Q · filed 2026-05-08 | $31.62B derived: sum of 2 quarters · filed 2026-05-08 | $47.40B derived: sum of 3 quarters · filed 2026-05-08 | $62.82B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $16.62B 10-K · filed 2026-02-20 | $32.39B derived: sum of 2 quarters · filed 2026-02-20 | $47.82B derived: sum of 3 quarters · filed 2026-08-03 | $61.16B 10-K · filed 2026-02-20 |
| 2025-09-30 | $15.78B 10-Q · filed 2025-11-04 | $31.20B derived: sum of 2 quarters · filed 2026-08-03 | $44.54B 10-Q · filed 2025-11-04 | $59.64B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $15.42B 10-Q · filed 2026-08-03 | $28.77B 10-Q · filed 2026-08-03 | $43.87B derived: sum of 3 quarters · filed 2026-08-03 | $58.33B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $13.34B 10-Q · filed 2026-05-08 | $28.45B derived: sum of 2 quarters · filed 2026-05-08 | $42.91B derived: sum of 3 quarters · filed 2026-05-08 | $57.37B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $15.10B 10-K · filed 2025-02-14 | $29.56B derived: sum of 2 quarters · filed 2025-11-04 | $44.02B derived: sum of 3 quarters · filed 2025-11-04 | $56.33B 10-K · filed 2026-02-20 |
| 2024-09-30 | $14.46B 10-Q · filed 2025-11-04 | $28.92B derived: sum of 2 quarters · filed 2025-11-04 | $41.23B 10-Q · filed 2025-11-04 | $55.53B derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $14.46B 10-Q · filed 2025-08-04 | $26.77B 10-Q · filed 2025-08-04 | $41.07B derived: sum of 3 quarters · filed 2025-08-04 | $55.00B derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | $12.31B 10-Q · filed 2025-05-09 | $26.61B derived: sum of 2 quarters · filed 2025-05-09 | $40.54B derived: sum of 3 quarters · filed 2025-05-09 | $54.40B derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $14.30B 10-K · filed 2024-02-20 | $28.23B derived: sum of 2 quarters · filed 2024-11-04 | $42.09B derived: sum of 3 quarters · filed 2024-11-04 | $54.32B 10-K · filed 2026-02-20 |
| 2023-09-30 | $13.93B 10-Q · filed 2024-11-04 | $27.79B derived: sum of 2 quarters · filed 2024-11-04 | $40.02B 10-Q · filed 2024-11-04 | $55.14B derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $13.87B 10-Q · filed 2024-08-07 | $26.09B 10-Q · filed 2024-08-07 | $41.21B derived: sum of 3 quarters · filed 2024-08-07 | $56.02B derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $12.22B 10-Q · filed 2024-05-03 | $27.35B derived: sum of 2 quarters · filed 2024-05-03 | $42.16B derived: sum of 3 quarters · filed 2024-05-03 | $56.74B derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $15.12B 10-K · filed 2023-02-17 | $29.93B derived: sum of 2 quarters · filed 2023-11-06 | $44.52B derived: sum of 3 quarters · filed 2023-11-06 | $58.05B 10-K · filed 2025-02-14 |
| 2022-09-30 | $14.81B 10-Q · filed 2023-11-06 | $29.39B derived: sum of 2 quarters · filed 2023-11-06 | $42.93B 10-Q · filed 2023-11-06 | $57.82B derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $14.58B 10-Q · filed 2023-08-07 | $28.12B 10-Q · filed 2023-08-07 | $43.01B derived: sum of 3 quarters · filed 2023-08-07 | $57.35B derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $13.54B 10-Q · filed 2023-05-05 | $28.42B derived: sum of 2 quarters · filed 2023-05-05 | $42.77B derived: sum of 3 quarters · filed 2023-05-05 | $56.73B derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $14.89B 10-K · filed 2022-02-18 | $29.23B derived: sum of 2 quarters · filed 2022-11-04 | $43.19B derived: sum of 3 quarters · filed 2022-11-04 | $56.20B 10-K · filed 2024-02-20 |
| 2021-09-30 | $14.34B 10-Q · filed 2022-11-04 | $28.30B derived: sum of 2 quarters · filed 2022-11-04 | $41.31B 10-Q · filed 2022-11-04 | $55.17B derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $13.96B 10-Q · filed 2022-08-04 | $26.97B 10-Q · filed 2022-08-04 | $40.83B derived: sum of 3 quarters · filed 2022-08-04 | $53.73B derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $13.01B 10-Q · filed 2022-05-06 | $26.87B derived: sum of 2 quarters · filed 2022-05-06 | $39.77B derived: sum of 3 quarters · filed 2022-05-06 | $50.20B derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $13.86B 10-K · filed 2021-02-19 | $26.76B derived: sum of 2 quarters · filed 2021-11-02 | $37.19B derived: sum of 3 quarters · filed 2021-11-02 | $45.80B 10-K · filed 2023-02-17 |
| 2020-09-30 | $12.90B 10-Q · filed 2021-11-02 | $23.33B derived: sum of 2 quarters · filed 2021-11-02 | $31.95B 10-Q · filed 2021-11-02 | $40.65B derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $10.43B 10-Q · filed 2021-08-02 | $19.04B 10-Q · filed 2021-08-02 | $27.75B derived: sum of 3 quarters · filed 2021-08-02 | $36.23B derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-03-31 | $8.62B 10-Q · filed 2021-05-07 | $17.32B derived: sum of 2 quarters · filed 2021-05-07 | $25.80B derived: sum of 3 quarters · filed 2021-05-07 | $34.06B derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $8.70B 10-K · filed 2020-02-21 | $17.18B derived: sum of 2 quarters · filed 2020-11-04 | $25.44B derived: sum of 3 quarters · filed 2020-11-04 | $33.27B 10-K · filed 2022-02-18 |
| 2019-09-30 | $8.48B 10-Q · filed 2020-11-04 | $16.73B derived: sum of 2 quarters · filed 2020-11-04 | $24.56B 10-Q · filed 2020-11-04 | $32.87B derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $8.26B 10-Q · filed 2020-08-04 | $16.08B 10-Q · filed 2020-08-04 | $24.39B derived: sum of 3 quarters · filed 2020-08-04 | $32.62B derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | $7.83B 10-Q · filed 2020-05-08 | $16.13B derived: sum of 2 quarters · filed 2020-05-08 | $24.37B derived: sum of 3 quarters · filed 2020-05-08 | $32.65B derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $8.30B 10-K · filed 2020-02-21 | $16.54B derived: sum of 2 quarters · filed 2020-02-21 | $24.82B derived: sum of 3 quarters · filed 2020-02-21 | $32.75B 10-K · filed 2021-02-19 |
| 2018-09-30 | $8.24B 10-K · filed 2020-02-21 | $16.51B derived: sum of 2 quarters · filed 2020-02-21 | $24.45B 10-Q · filed 2019-11-06 | $32.19B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $8.28B 10-K · filed 2020-02-21 | $16.21B 10-Q · filed 2019-08-05 | $23.95B derived: sum of 3 quarters · filed 2020-02-21 | $30.95B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $7.93B 10-K · filed 2020-02-21 | $15.67B derived: sum of 2 quarters · filed 2020-02-21 | $22.67B derived: sum of 3 quarters · filed 2020-02-21 | $29.61B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $7.74B 10-K · filed 2019-02-27 | $14.73B derived: sum of 2 quarters · filed 2019-02-27 | $21.68B derived: sum of 3 quarters · filed 2019-02-27 | $28.22B 10-K · filed 2020-02-21 |
| 2017-09-30 | $7.00B 10-K · filed 2019-02-27 | $13.94B derived: sum of 2 quarters · filed 2019-02-27 | $20.48B 10-Q · filed 2018-11-07 | $27.27B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $6.94B 10-K · filed 2019-02-27 | $13.48B 10-Q · filed 2018-08-07 | $20.28B derived: sum of 3 quarters · filed 2019-02-27 | $26.71B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $6.54B 10-K · filed 2019-02-27 | $13.33B derived: sum of 2 quarters · filed 2019-02-27 | $19.77B derived: sum of 3 quarters · filed 2019-02-27 | $26.22B derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $6.80B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $13.23B derived: sum of 2 quarters · filed 2019-02-27 | $19.68B derived: sum of 3 quarters · filed 2019-02-27 | $25.64B 10-K · filed 2019-02-27 |
| 2016-09-30 | $6.43B 10-Q · filed 2017-11-07 | $12.88B derived: sum of 2 quarters · filed 2017-11-07 | $18.84B 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $6.45B 10-Q · filed 2017-08-07 | $12.41B 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $5.96B 10-Q · filed 2017-05-05 | |||
| 2015-09-30 | $5.94B 10-Q · filed 2016-11-07 | $11.42B derived: sum of 2 quarters · filed 2016-11-07 | $16.46B 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $5.47B 10-Q · filed 2016-08-05 | $10.52B 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | $5.04B 10-Q · filed 2016-05-06 | |||
| 2014-09-30 | $5.02B 10-Q · filed 2015-11-06 | $9.95B derived: sum of 2 quarters · filed 2015-11-06 | $14.51B 10-Q · filed 2015-11-06 | |
| 2014-06-30 | $4.93B 10-Q · filed 2015-08-07 | $9.49B 10-Q · filed 2015-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |